Literature DB >> 21986843

Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage.

B Britt-Compton, T T Lin, G Ahmed, V Weston, R E Jones, C Fegan, D G Oscier, T Stankovic, C Pepper, D M Baird.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21986843     DOI： 10.1038/leu.2011.281

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Oxidative stress as a therapeutic perspective for ATM-deficient chronic lymphocytic leukemia patients.

Authors:  Veronika Navrkalova; Leona Raskova Kafkova; Vladimir Divoky; Sarka Pospisilova
Journal:  Haematologica       Date:  2015-08       Impact factor: 9.941

2.  Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis.

Authors:  M Ratnaparkhe; M Hlevnjak; T Kolb; A Jauch; K K Maass; F Devens; A Rode; V Hovestadt; A Korshunov; A Pastorczak; W Mlynarski; S Sungalee; J Korbel; J Hoell; U Fischer; T Milde; C Kramm; M Nathrath; K Chrzanowska; E Tausch; M Takagi; T Taga; S Constantini; J Loeffen; J Meijerink; S Zielen; G Gohring; B Schlegelberger; E Maass; R Siebert; J Kunz; A E Kulozik; B Worst; D T Jones; S M Pfister; M Zapatka; P Lichter; A Ernst
Journal:  Leukemia       Date:  2017-02-15       Impact factor: 11.528

3.  ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.

Authors:  Matthew J J Rose-Zerilli; Jade Forster; Helen Parker; Anton Parker; Ana E Rodríguez; Tracy Chaplin; Anne Gardiner; Andrew J Steele; Andrew Collins; Bryan D Young; Anna Skowronska; Daniel Catovsky; Tatjana Stankovic; David G Oscier; Jonathan C Strefford
Journal:  Haematologica       Date:  2014-02-28       Impact factor: 9.941

4.  ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres.

Authors:  Veronika Navrkalova; Emma Young; Panagiotis Baliakas; Lenka Radova; Lesley-Ann Sutton; Karla Plevova; Larry Mansouri; Viktor Ljungström; Stavroula Ntoufa; Zadie Davis; Gunnar Juliusson; Karin E Smedby; Chrysoula Belessi; Panagiotis Panagiotidis; Tasoula Touloumenidou; Frederic Davi; Anton W Langerak; Paolo Ghia; Jonathan C Strefford; David Oscier; Jiri Mayer; Kostas Stamatopoulos; Sarka Pospisilova; Richard Rosenquist; Martin Trbusek
Journal:  Haematologica       Date:  2016-06-16       Impact factor: 9.941

Review 5.  The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia.

Authors:  S N Malek
Journal:  Oncogene       Date:  2012-09-24       Impact factor: 9.867

Review 6.  The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation.

Authors:  Limengmeng Wang; Haowen Xiao; Xing Zhang; Chong Wang; He Huang
Journal:  J Hematol Oncol       Date:  2014-08-20       Impact factor: 17.388

7.  Alternative end joining, clonal evolution, and escape from a telomere-driven crisis.

Authors:  Eric A Hendrickson; Duncan M Baird
Journal:  Mol Cell Oncol       Date:  2015-01-28

Review 8.  Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy.

Authors:  Sara Martinelli; Antonio Cuneo; Luca Formigaro; Maurizio Cavallari; Enrico Lista; Francesca Maria Quaglia; Maria Ciccone; Antonella Bardi; Eleonora Volta; Elisa Tammiso; Elena Saccenti; Olga Sofritti; Giulia Daghia; Massimo Negrini; Melissa Dabusti; Paolo Tomasi; Sabrina Moretti; Francesco Cavazzini; Gian Matteo Rigolin
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-15       Impact factor: 2.576

9.  Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish population.

Authors:  Maria Peña-Chilet; Maite Blanquer-Maceiras; Maider Ibarrola-Villava; Conrado Martinez-Cadenas; Manuel Martin-Gonzalez; Cristina Gomez-Fernandez; Matias Mayor; Juan Antonio Aviles; Ana Lluch; Gloria Ribas
Journal:  BMC Cancer       Date:  2013-03-27       Impact factor: 4.430

10.  Telomere status in chronic lymphocytic leukemia with TP53 disruption.

Authors:  Romain Guièze; Mélanie Pages; Lauren Véronèse; Patricia Combes; Richard Lemal; Mathilde Gay-Bellile; Martine Chauvet; Mary Callanan; Fabrice Kwiatkowski; Bruno Pereira; Philippe Vago; Jacques-Olivier Bay; Olivier Tournilhac; Andreï Tchirkov
Journal:  Oncotarget       Date:  2016-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.